Herpes simplex virus oncolytic vaccine therapy in melanoma

Bibliography

• Balch CM. Cutaneous melanoma. 5th edition. Quality Medical Publishing, St. Louis, MO; 2009
   Google Scholar
• Balch CM, Soong SJ, Gershenwald JE, Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;10:3622-34
   Google Scholar
• Riker AI, Radfar S, Liu S, Immunotherapy of melanoma: a critical review of current concepts and future strategies. Expert Opin Biol Ther 2007;7:345-58
   PubMed Web of Science ®Google Scholar
• Korn EL, Liu PY, Lee SJ, Meta-analysis of Phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008;26:527-34
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15
   PubMed Web of Science ®Google Scholar
• Ralph SJ. An update on malignant melanoma vaccine research: insights into mechanisms for improving the design and potency of melanoma therapeutic vaccines. Am J Clin Dermatol 2007;8:123-41
   PubMed Web of Science ®Google Scholar
• Eisenberger A, Elliott BM, Kaufman HL. Viral vaccines for cancer immunotherapy. Hematol Oncol Clin North Am 2006;20:661-87
   PubMed Web of Science ®Google Scholar
• Jilaveanu LB, Aziz SA, Kluger HM. Chemotherapy and biologic therapies for melanoma: do they work? Clin Dermatol 2009;27:614-25
   PubMed Web of Science ®Google Scholar
• Brower V. BRAF inhibitors: research accelerates in wake of positive findings. J Natl Cancer Inst 2010;102:214-5
   PubMed Web of Science ®Google Scholar
• Chang AE, Li Q, Bishop DK, Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 2000;11:839-50
   PubMed Web of Science ®Google Scholar
• Soiffer R, Hodi FS, Haluska F, Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003;21:3343-50
   PubMed Web of Science ®Google Scholar
• Luiten RM, Kueter EW, Mooi W, Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol 2005;23:8978-91
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Ugurel S, Schuler-Thurner B, Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006;17:563-70
   PubMed Web of Science ®Google Scholar
• Porgador A, Irvine KR, Iwasaki A, Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 1998;188:1075-82
   PubMed Web of Science ®Google Scholar
• Chattergoon MA, Robinson TM, Boyer JD, Weiner DB. Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells. J Immunol 1998;160:5707-18
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Deck RR, Dewitt CM, Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology 1996;89:59-67
   PubMed Web of Science ®Google Scholar
• Fu TM, Ulmer JB, Caulfield MJ, Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med 1997;3:362-71
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 2003;14:709-14
   PubMed Web of Science ®Google Scholar
• Triozzi PL, Aldrich W, Allen KO, Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse. J Immunother 2005;28:382-8
   PubMed Web of Science ®Google Scholar
• Liu BL, Robinson M, Han ZQ, ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003;10:292-303
   PubMed Web of Science ®Google Scholar
• Leib DA, Harrison TE, Laslo KM, Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo. J Exp Med 1999;189:663-72
   PubMed Web of Science ®Google Scholar
• Farassati F, Yang AD, Lee PW. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 2001;3:745-50
   PubMed Web of Science ®Google Scholar
• Brown SM, MacLean AR, Aitken JD, Harland J. ICP34.5 influences herpes simplex virus type 1 maturation and egress from infected cells in vitro. J Gen Virol 1994;75(Pt 12):3679-86
   PubMed Web of Science ®Google Scholar
• Brown SM, MacLean AR, McKie EA, Harland J. The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyD116 complex with proliferating cell nuclear antigen through the 63-amino-acid domain conserved in ICP34.5, MyD116, and GADD34. J Virol 1997;71:9442-9
   PubMed Web of Science ®Google Scholar
• Rampling R, Cruickshank G, Papanastassiou V, Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000;7:859-66
   PubMed Web of Science ®Google Scholar
• Markert JM, Medlock MD, Rabkin SD, Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7:867-74
   PubMed Web of Science ®Google Scholar
• Papanastassiou V, Rampling R, Fraser M, The potential for efficacy of the modified (ICP 34.5–) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther 2002;9:398-406
   PubMed Web of Science ®Google Scholar
• Cassady KA, Gross M. The herpes simplex virus type 1 U(S)11 protein interacts with protein kinase R in infected cells and requires a 30-amino-acid sequence adjacent to a kinase substrate domain. J Virol 2002;76:2029-35
   PubMed Web of Science ®Google Scholar
• Harrington K, Hingorani M, Tanay M, Phase I/II dose escalation study of Onco VexGM-CSF and chemoradiotherapy in untreated stage III/IV squamous cell cancer of the head and neck. In: American Society of Clinical Oncology (ASCO) Annual Meeting, 1 June 2009. J Clin Oncol 2009;27(15s): abstract 6018
   Google Scholar
• Hu JC, Coffin RS, Davis CJ, A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006;12:6737-47
   PubMed Web of Science ®Google Scholar
• Senzer NN, Kaufman HL, Amatruda T, Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009;27:5763-71
   PubMed Web of Science ®Google Scholar
• Eager R, Nemunaitis J. GM-CSF gene-transduced tumor vaccines. Mol Ther 2005;12:18-27
   PubMed Web of Science ®Google Scholar
• Han ZQ, Assenberg M, Liu BL, Development of a second-generation oncolytic herpes simplex virus expressing TNFalpha for cancer therapy. J Gene Med 2007;9:99-106
   PubMed Web of Science ®Google Scholar
• Simpson GR, Han Z, Liu B, Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Cancer Res 2006;66:4835-42
   PubMed Web of Science ®Google Scholar
• MacKie RM, Stewart B, Brown SM. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 2001;357:525-6
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kim DW, DeRaffele G, Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010;17:718-30
   PubMed Web of Science ®Google Scholar
• Saenger YM, Wolchok JD. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun 2008;8:1
   PubMedGoogle Scholar
• Jaffee EM, Pardoll DM. Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines. Methods 1997;12:143-53
   PubMed Web of Science ®Google Scholar
• Nevala WK, Vachon CM, Leontovich AA, Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res 2009;15:1931-9
   PubMed Web of Science ®Google Scholar
• Chaussabel D, Quinn C, Shen J, A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 2008;29:150-64
   PubMed Web of Science ®Google Scholar